Subscriber Content Preview | Request a free trialSearch  


Antitrust protections no 'road map' for merger challenges, regulators say

Common fear that merger agreement covenants will tip off officials to competitive harms called unfounded. Continue reading

Mylan bids $29B for generics drug company Perrigo in latest big pharma deal

The bid, made public under Irish law, provides for $205 per share for Perrigo's stock. Continue reading

Novartis makes history and the biosimilar industry looks even more attractive

Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets. Continue reading

Concordia Healthcare acquires Covis Pharma for $1.2B in cash

Concordia picks up 18 drugs in acquisition of PE-backed Covis, as big deals in the pharmaceuticals space continue. Continue reading

Piercing the once-impregnable steel veil at dual-share companies

Insurgents are finding ways to apply pressure, especially where the nature of the ownership is depressing stock prices. Continue reading

Three companies benefiting from Obamacare's expanded access to mental health services

The law made access to treatment for addiction and other problems widely available. More patients with the means to pay for care is creating greater opportunities for providers. Continue reading

Mallinckrodt adds Ikaria in $2.3B hospital treatment deal

The target is owned by a group led by Madison Dearborn Partners, which bought into Ikaria in 2013. Continue reading

Cardinal Health acquires Johnson & Johnson's Cordis in a $1.9B deal

Sale of the cardiac device company is part of Johnson & Johnson's strategy of trimming its portfolio. Continue reading

Battle rages over whether an old drug can be new again

Takeover candidate United Therapeutics fights Sandoz over patents for treating a rare disorder. Continue reading

Stryker and Smith & Nephew are the stars to watch in medtech's 2015 merger dance

After a robust year of mega-deals In 2014, mid-size device makers are expected to seek partners, fueling even further consolidation. Continue reading

Valeant follows failed Allergan bid with $14.5B Salix acquisition

Following last year's failed attempt to purchase Allergan, the Canadian pharmaceutical giant continues its acquisition strategy with its latest deal. Continue reading

Activist Investing: Impact on M&A

Armed with more than $100 billion in capital and a tenacity to match, activist money managers have become an investment juggernaut. Continue reading

Meet the journalists

William Blair's Dan Shedivy sits down to talk M&A in the healthcare services sector

Middle Market healthcare deals stayed strong in 2014 but were relative ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

The Deal’s senior journalists host the industry's leading M&A forecasting event, an invitation-only gathering of influential members of the deal community discussing the outlook for dealmaking in the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!